Loading
companiesCompany
United Therapeutics
United Therapeutics is a Maryland company known for pulmonary hypertension medicines that also makes dinutuximab (Unituxin), the anti-GD2 antibody that became standard for high-risk neuroblastoma in children.
Also called: United Therapeutics CorporationUnither Pharmaceuticals
Overview
United Therapeutics, founded in 1996 and headquartered in Silver Spring, Maryland, built its business on treatments for pulmonary arterial hypertension and now works on manufactured organs. In oncology it commercialises dinutuximab (Unituxin), the chimeric anti-GD2 antibody developed with the Children's Oncology Group and approved in 2015 for high-risk neuroblastoma after a phase 3 trial showed better event-free survival. ClinicalTrials.gov lists the company as lead sponsor of a phase 3 cancer trial.
Headquarters
Silver Spring, MD, US
Scorecard
All companies#204of 1244 companies, score 27
- approved products +6
- targets +2
- modalities +2
- regions +5
- registry trials +12
1 approved, 0 in phase 3, 0 earlier, 1 targets, 34 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1996
ApprovedMonoclonal antibody (anti-GD2, chimeric)
Dinutuximab (ch14.18) / dinutuximab beta · Unituxin / Qarziba (EU)
The antibody that raised cure rates in high-risk childhood neuroblastoma by about 20 points when given after transplant with immune boosters and retinoid.
Similar pages
- Key paperANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
- Key paperANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
- PairingCaution: IL-2 added to anti-GD2 therapy
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
- CompanyPregLem
- TermMIBG Curie and SIOPEN scores
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
- CompanyAgennix
- CompanyLisata Therapeutics
cancers
drugs
ApprovedMonoclonal antibody (anti-GD2, chimeric)
Dinutuximab (ch14.18) / dinutuximab beta · Unituxin / Qarziba (EU)